Pleomorphic Malignant Fibrous Histiocytoma of Heart

Pleomorphic Malignant Fibrous Histiocytoma of Heart

Article
Heart & Vascular Health
Diseases & Conditions
+2
Contributed byMaulik P. Purohit MD MPHDec 17, 2018

What are the other Names for this Condition? (Also known as /Synonyms)

  • Malignant Fibrous Histiocytoma of Heart, Pleomorphic Variant
  • Primary Pleomorphic Cardiac Malignant Fibrous Histiocytoma
  • Undifferentiated Pleomorphic Cardiac Sarcoma

What is Pleomorphic Malignant Fibrous Histiocytoma of Heart? (Definition/Background Information)

  • Pleomorphic Malignant Fibrous Histiocytoma of Heart is a high-grade malignancy of the heart. A malignant fibrous histiocytoma (MFH) is the most common sarcoma affecting the heart, after an angiosarcoma
  • The tumors are mostly observed in middle-aged adults. Currently, there are no identified risk factors or cause for Pleomorphic Malignant Fibrous Histiocytoma of Heart
  • In up to 80% of the cases, the tumors are observed to form in the left atrium (upper chamber of the heart). Large-sized tumors may cause chest pain, lung congestion, and breathing difficulties
  • The treatment of Pleomorphic Malignant Fibrous Histiocytoma of Heart is undertaken through surgery. However, since it is difficult to remove the entire tumor, chemotherapy and/or radiation therapy may be necessary
  • The prognosis of Pleomorphic Malignant Fibrous Histiocytoma of Heart is generally poor due to local invasion and metastasis of the malignancy to various body sites

Malignant fibrous histiocytoma (MFH):

  • Malignant fibrous histiocytoma is a high-grade mesenchymal tumor. The mesenchymal tissue is the source for bone, muscle, connective tissue, and dermis of skin
  • When it is marked by distinct cellular pleomorphism, the tumor is called Pleomorphic MFH, which is the most common subtype (comprising 90% ) of MFH found in the heart
  • The other subtypes (10%) of malignant fibrous histiocytoma found in the heart include the giant cell type and myxoid type

Who gets Pleomorphic Malignant Fibrous Histiocytoma of Heart? (Age and Sex Distribution)

  • Pleomorphic Malignant Fibrous Histiocytoma of Heart is the most second common malignant tumor of the heart; even though malignant tumors of the heart by itself are a rare occurrence
  • The tumor occurs in adults in the 20-80 years age category (mean age 45 years); rarely, the tumor has been observed in infants and children
  • Both males and females are equally affected
  • No racial or ethnic preference is noted

What are the Risk Factors for Pleomorphic Malignant Fibrous Histiocytoma of Heart? (Predisposing Factors)

  • Currently, no specific risk factors are noted for the development of Pleomorphic Malignant Fibrous Histiocytoma of Heart

It is important to note that having a risk factor does not mean that one will get the condition. A risk factor increases ones chances of getting a condition compared to an individual without the risk factors. Some risk factors are more important than others.

Also, not having a risk factor does not mean that an individual will not get the condition. It is always important to discuss the effect of risk factors with your healthcare provider.

What are the Causes of Pleomorphic Malignant Fibrous Histiocytoma of Heart? (Etiology)

The exact cause and mechanism of formation of Pleomorphic Malignant Fibrous Histiocytoma of Heart is unknown. However, extra-cardiac tumors have shown genetic involvement.

  • In general, it is known that cancers form when normal, healthy cells begin transforming into abnormal cells - these cancer cells grow and divide uncontrollably (and lose their ability to die), resulting in the formation of a mass or a tumor
  • The transformation of normally healthy cells into cancerous cells may be the result of genetic mutations. Mutations allow the cancer cells to grow and multiply uncontrollably to form new cancer cells
  • These tumors can invade nearby tissues and adjoining body organs, and even metastasize and spread to other regions of the body

What are the Signs and Symptoms of Pleomorphic Malignant Fibrous Histiocytoma of Heart?

The signs and symptoms of Pleomorphic Malignant Fibrous Histiocytoma of Heart are based on the location of the tumor in the heart. Small tumors may not be present any signs and symptoms. In such cases, the tumors may be discovered incidentally.

The features of Pleomorphic MFH of Heart may include:

  • A majority of the tumors (~80%) are located in the left atrium, on the atrial wall or septum
  • Other locations include the pericardium, pulmonary valve, and ventricle
  • The presence of lobulated multiple masses that are soft/firm are noted; some tumors are pedunculated
  • Large-sized tumors that grow up to 10 cm have been observed
  • Some may even grow into the pulmonary vein or lung tissue
  • Since mostly the left side of the heart is affected by the tumor, the signs and symptoms include lung congestion, blockage of pulmonary vein, and narrowing of mitral valve (due to compression effect of the tumor)
  • Chest pain, breathing difficulty, blood in cough, dizziness, and fainting may also be present

How is Pleomorphic Malignant Fibrous Histiocytoma of Heart Diagnosed?

The diagnosis of Pleomorphic Malignant Fibrous Histiocytoma of Heart is performed by excluding other cardiac tumors. Studies indicate that the tumor may resemble osteosarcoma of the heart.

The following tools may be used towards establishing a diagnosis:

  • Complete evaluation of family (medical) history, along with a thorough physical examination; including examination of the heart, with special emphasis to signs such as abnormal heart sounds
  • Transthoracic echocardiography (TTE): This procedure uses sound waves to create a motion picture of the heart movement
  • Electrocardiogram (EKG or ECG): It is used to measure the electrical activity of the heart, to detect arrhythmias
  • Electrophysiological studies of the heart to determine where arrhythmia is getting generated in the heart is often helpful
  • MRI scan and CT scan of the heart: These imaging studies can indicate if the tumor is a lipoma or not, and one may be able to mark a strong suspicion of Pleomorphic Malignant Fibrous Histiocytoma of Heart
  • Doppler ultrasound: Sound waves are used to measure the speed and direction of blood flow
  • Tissue biopsy of the tumor:
    • A biopsy of the tumor is performed and sent to a laboratory for a pathological examination. A pathologist examines the biopsy under a microscope. After putting together clinical findings, special studies on tissues (if needed) and with microscope findings, the pathologist arrives at a definitive diagnosis. Examination of the biopsy under a microscope by a pathologist is considered to be gold standard in arriving at a conclusive diagnosis
    • Biopsy specimens are studied initially using Hematoxylin and Eosin staining. The pathologist then decides on additional studies depending on the clinical situation
    • Sometimes, the pathologist may perform additional studies, which may include immunohistochemical stains and molecular studies to assist in the diagnosis

Note: Due to the rarity of malignant fibrous histiocytoma tumors, it can cause diagnostic challenges during a frozen section biopsy.

Many clinical conditions may have similar signs and symptoms. Your healthcare provider may perform additional tests to rule out other clinical conditions to arrive at a definitive diagnosis.

What are the possible Complications of Pleomorphic Malignant Fibrous Histiocytoma of Heart?

Complications due to Pleomorphic Malignant Fibrous Histiocytoma of Heart could include:

  • Congestive heart failure, depending on the location of the tumor in the heart
  • Increased risk for thromboembolism (blood clot obstructing a blood vessel)
  • Metastasis of the tumor to other sites in the body including to the lungs, lymph nodes, kidney, skin, and thyroid gland; any part of the body may be affected
  • Recurrence of the tumor after surgery, when the entire tumor is not removed
  • Blood loss during invasive treatment methods may be heavy
  • Damage of vital nerves, blood vessels, and surrounding structures during surgery
  • Side effects from chemotherapy (toxicity), radiation therapy

How is Pleomorphic Malignant Fibrous Histiocytoma of Heart Treated?

The treatment measures for Pleomorphic Malignant Fibrous Histiocytoma of Heart may include a combination of the following:

  • Surgery: Complete excision where possible is attempted; though, it is difficult for the heart tumor to be removed completely
  • Therefore, radiation therapy and/or chemotherapy are provided. But, such therapy results are stated to be variable
  • Embolization (clotting the vessels in the tumor) may be used to provide temporary relief from the symptoms and reduce blood loss during a surgical procedure
  • Heart transplantation may be undertaken in some cases; when no metastasis has occurred and the primary tumor, which cannot be surgically removed, is confined to the heart
  • Follow-up care with regular screening and check-ups are important

How can Pleomorphic Malignant Fibrous Histiocytoma of Heart be Prevented?

  • Current medical research has not established a way of preventing the formation of Pleomorphic Malignant Fibrous Histiocytoma of Heart
  • Due to its metastasizing potential and recurrence rate, regular medical screening at periodic intervals with blood tests, scans, and physical examinations, are mandatory for those who have already been treated for this tumor

What is the Prognosis of Pleomorphic Malignant Fibrous Histiocytoma of Heart? (Outcomes/Resolutions)

  • The prognosis of Pleomorphic Malignant Fibrous Histiocytoma of Heart is generally poor; most cases with local invasion or metastasis are fatal despite surgery to remove the tumors
  • The survival period following diagnosis of the tumor ranges from 5-18 months. Death mostly occurs due to spread of cancer, large size of tumor, or severely affected function of the heart
  • Nevertheless, the prognosis depends on a combination of factors, such as:
    • Age of the individual
    • Grade of the tumor: It is considered as a helpful parameter in predicting the prognosis
    • Tumor size and location
    • Its Ki-67 value - a protein found in cells that is a good indicator of how fast the tumor cells are growing. The Ki-67 value is determined by a pathologist and is usually mentioned in the pathology report
    • Response to treatment and medical therapy

Additional and Relevant Useful Information for Pleomorphic Malignant Fibrous Histiocytoma of Heart:

  • Pleomorphic Malignant Fibrous Histiocytoma of Heart is also known as Undifferentiated Pleomorphic Sarcoma of Heart
  • Primary tumors of heart are rare and they account for only 5% of heart tumors. Metastatic tumors to the heart are far more common
Was this article helpful

On the Article

Maulik P. Purohit MD MPH picture
Approved by

Maulik P. Purohit MD MPH

Assistant Medical Director, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!